Innovative tools are needed to alleviate the burden of mosquito-borne diseases, and strategies that target the pathogen are being considered. A possible tactic is the use of Wolbachia, a maternally inherited, endosymbiotic bacterium that can (but does not always) suppress diverse pathogens when introduced to naive mosquito species. We investigated effects of somatic Wolbachia (strain wAlbB) infection on Rift Valley fever virus (RVFV) in Culex tarsalis mosquitoes. When compared to Wolbachia-uninfected mosquitoes, there was no significant effect of Wolbachia infection on RVFV infection, dissemination, or transmission frequencies, nor on viral body or saliva titers. Within Wolbachia-infected mosquitoes, there was a modest negative correlation between RVFV body titers and Wolbachia density, suggesting that Wolbachia may slightly suppress RVFV in a density-dependent manner in this mosquito species. These results are contrary to previous work in the same mosquito species, showing Wolbachia-induced enhancement of West Nile virus infection rates. Taken together, these results highlight the importance of exploring the breadth of pathogen modulations induced by Wolbachia.
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Introduction
Globally, mosquito-borne diseases are a major health burden. To decrease mosquito populations, control programs often use integrated vector management practices including adulticide and larvicide application, source reduction, and biological control [1] . However, these mosquito control methods are losing efficacy due to increasing insecticide resistance and changes in mosquito behavior [2] [3] [4] . With these concerns, novel and sustainable control methods are under investigation, including strategies that target the pathogen [5, 6] . Wolbachia is a maternally-inherited endosymbiotic bacterium that infects a large number of insects and other invertebrates [7] . Infection by Wolbachia can cause broad effects on host physiology. For example, natural Wolbachia infections in fruit flies protect against pathogen-induced mortality [8, 9] . When experimentally transferred to uninfected mosquitoes, Wolbachia can suppress infection or transmission of viruses, Plasmodium parasites, and filarial nematodes [10] [11] [12] [13] . Wolbachia also manipulates host reproduction in ways that allow it to spread through and persist in insect populations [14] .
Investigations using Wolbachia-infected mosquitoes as a control method for dengue virus are underway [15] , and field trials in Australia have indicated that Wolbachia can spread to near-fixation in naturally uninfected populations of Aedes aegypti mosquitoes [16, 17] . These Wolbachia-infected Ae. aegypti populations can persist years after release, and mosquitoes retain the dengue virus-blocking phenotype [18] . Similar field experiments are being conducted in several other countries, but not all have reported successful replacement of the uninfected population with Wolbachia-infected mosquitoes [19] .
The effects of Wolbachia-induced pathogen interference may differ depending on mosquito species, Wolbachia strain, pathogen type, and environment conditions [20] [21] [22] . For example, in Anopheles gambiae, transient somatic infection of the Wolbachia strain wAlbB inhibits Plasmodium falciparum but enhances Plasmodium berghei parasites [22, 23] . Enhancement phenotypes have been observed in Anopheles, Culex, and Aedes mosquitoes, and across several malaria species and virus families [20, 22, [24] [25] [26] [27] . Thus, it is important to examine the range of Wolbachia-induced phenotypes so that efficacy of disease control efforts using Wolbachiainduced pathogen interference are not impeded.
Previous work has demonstrated that somatic Wolbachia (strain wAlbB) infections in Culex tarsalis (Yolo strain) enhanced West Nile virus (WNV) infection rates [24] . To better understand the range of Wolbachia-induced phenotypes, we investigated the effects of wAlbB on Rift Valley fever virus (RVFV) infection in Cx. tarsalis. RVFV is a member of the genus Phlebovirus in the family Bunyaviridae and predominately affects domestic ruminants, causing severe economic losses in the livestock industry and human morbidity in Africa and the Middle East [28] [29] [30] . Additionally, models and laboratory studies have suggested the United States may have environmental conditions and mosquito vectors that would permit RVFV introduction and invasion [31] [32] [33] [34] . Cx. tarsalis are abundant in the western U.S. and are highly competent laboratory vectors for RVFV [33] [34] [35] . We assessed the ability of Wolbachia to affect RVFV infection, dissemination, and transmission within Cx. tarsalis at two time points and evaluated relationships between viral titer and Wolbachia density in mosquitoes.
Materials and methods

Ethics statement
Mosquitoes were maintained on commercially obtained anonymous human blood using a membrane feeder (Biological Specialty Corporation, Colmar, PA). RVFV experiments were performed under biosafety-level 3 (BSL-3) and arthropod-containment level 3 (ACL3) conditions.
Research 
Mosquitoes and Wolbachia
The Culex tarsalis colony used for all experiments was derived from field mosquitoes collected in Yolo County, CA in 2009. Mosquitoes were reared and maintained at 27˚C ± 1˚C, 12:12 hr light:dark diurnal cycle at 80% relative humidity in 30×30×30 cm cages. The wAlbB Wolbachia strain was purified from An. gambiae Sua5B cells according to published protocols [36] . Wolbachia viability and density was assessed using the LIVE/DEAD BacLight Bacterial Viability Kit (Invitrogen, Carlsbad, CA) and a hemocytometer. The RVFV vector competence experiment was replicated three times with different hamsters, and wAlbB concentrations for those replicates as follows: replicate one, 2.5 × 10 9 bacteria/ml; replicate two, 2.5 × 10 9 bacteria/ml; replicate three, 5.0 × 10 9 bacteria/ml. Two-to 4-day-old adult female Cx. tarsalis were anesthetized with CO 2 and intrathoracically injected with approximately 0.1 μl of either suspended wAlbB or Schneider's insect media (Sigma Aldrich, Saint Louis, MO) as a control. Mosquitoes were provided with 10% sucrose ad libitum and maintained at 27˚C in a growth chamber.
Vector competence for RVFV
RVFV strain ZH501 was isolated from the blood of a fatal human case in Egypt in 1977 [37] . Adult female Syrian hamsters were inoculated intraperitoneally with 0.2 ml of a suspension containing RVFV in diluent (10% heat-inactivated fetal bovine serum in Medium 199 with Earle's salts [Invitrogen] , sodium bicarbonate, and antibiotics) containing approximately 10 5 plaque-forming units (PFU) per ml of RVFV. Approximately 28-30 hr post-inoculation, infected hamsters were anesthetized with a suspension of ketamine, acepromazine, and xylazine. A single viremic hamster was placed across two 3.8-liter cardboard cages containing either Wolbachia-infected Cx. tarsalis or control-injected Cx. tarsalis, treatments to which the experimenter was blinded. Mosquitoes were allowed to feed for one hour. After this period, hamsters were removed, a blood sample taken to determine viremia, and hamsters were euthanized.
After feeding, mosquitoes were anesthetized with CO 2 and examined for feeding status; partially or non-blood fed females were discarded. For all replicates, one blood fed mosquito from each treatment was sampled to test for input viral titers. Mosquitoes were sampled at 7 and 14 days post-blood feeding. On day 7, mosquitoes were anesthetized with CO 2 and had their legs removed; each set of legs was placed into one 2-ml microcentrifuge tube containing 1 ml of mosquito diluent (20% heat-inactivated fetal bovine serum [FBS] in Dulbecco's phosphate-buffered saline, 50 μg/ml penicillin streptomycin, and 2.5 μg/ml fungizone). Bodies were placed separately into 2-ml microcentrifuge tubes (Eppendorf, Hauppauge, NY) containing 1 ml of mosquito diluent. On day 14, bodies and legs were collected in the same manner as day 7, except that prior to placing bodies into microcentrifuge tubes, saliva was collected from mosquitoes by positioning the proboscis of each mosquito into a capillary tube containing approximately 10 μl of a 1:1 solution of 50% sucrose and FBS. After 30 minutes, the contents were expelled in individual microcentrifuge tubes containing 0.3 ml of mosquito diluent. A 5 mm stainless steel bead (Qiagen, Valencia, CA) was placed into all microcentrifuge tubes that contained mosquito bodies and legs, homogenized in a mixer mill (Retsch, Haan, Germany) for 30 seconds at 24 cycles per second, and centrifuged for 1 minute at 8000 rpm. All mosquito bodies, legs, and saliva were stored at -80˚C until assayed.
Samples were tested for RVFV infectious particles by plaque assay on Vero cells according to previous published protocols [38] . Serial dilutions were prepared for all mosquito body, leg, and saliva samples. One hundred microliters of each dilution was inoculated onto Vero cell culture monolayers. Inoculated plates were incubated at 37˚C for 1 hr and an agar overlay was added (1X EBME, 0.75% agarose, 7% FBS, 1% penicillin streptomycin, and 1% nystatin). Plates were incubated at 37˚C for 3 days and then a second overlay (1X EBME, 0.75% agarose, and 4% neutral red) was added. Plaques were counted 24 hr after application of the second overlay and titers calculated.
Quantitative real-time PCR of Wolbachia density
To evaluate relationships between Wolbachia density and RVFV titer, we measured wAlbB levels in individual mosquitoes. DNA was extracted from 200 μl of mosquito body homogenate using the DNeasy blood and tissue kit (Qiagen) and used as template for qPCR on a Rotor-Gene Q (Qiagen) with the PerfeCta SYBR FastMix kit (Quanta Biosciences, Beverly, MA) or on ABI 7500 with Power SYBR green master mix (Applied Biosystems, Foster City, CA). The qPCR assays were performed in 10μl reactions and amplification was carried out using a standardized program at 95˚C for 5 min, 40 cycles of 95˚C for 10 sec, 60˚C for 15 sec, and 72˚C for 10 sec. Wolbachia DNA was amplified with primers Alb-GF and Alb-GR [39] and was normalized to the Cx. tarsalis actin gene by using qGene software [24, 40] . qPCRs were performed in duplicate.
Statistical analyses
Infection, dissemination, and transmission rates were compared between Wolbachia-infected and control Cx. tarsalis, and between replicates with Fisher's exact tests. Due to violations of assumptions needed for parametric tests, Mann-Whitney U was used to compare the following data sets: RVFV body titers between Wolbachia-infected and control mosquitoes, RVFV body titers between RVFV-positive saliva and RVFV-negative saliva, RVFV body titers over time, and Wolbachia density over time. Unpaired t-tests were used to analyze data that passed normality tests, including the comparison of RVFV saliva titers between Wolbachia-infected and control mosquitoes. To determine relationships between Wolbachia density and RVFV body titer, the Spearman rank correlation test was used, as assumptions for Pearson correlation were violated. All statistical analyses were performed in GraphPad Prism version 7 for Windows (GraphPad Software, San Diego, CA).
Results
Vector competence for RVFV
After all hamster feeds (i.e., replicates), one blood fed mosquito from each treatment was tested for input RVFV titers on the day of blood feeding. These day 0 RVFV titer results for Wolbachia-infected Cx. tarsalis were as follows: replicate 1, 2.50 × 10 2 PFU/ml; replicate 2, 7.00 × 10 6 PFU/ml; replicate 3, 1.00 × 10 2 PFU/ml. , and 10 3 PFU/ml, respectively.
To determine RVFV vector competence of Wolbachia-infected and Wolbachia-uninfected Cx. tarsalis, we examined frequencies of RVFV-positive bodies (Fig 1A), legs (Fig 1B) , and saliva ( Fig 1C) . Infection rate is the proportion of mosquito bodies that contained infectious RVFV. Dissemination and transmission rates are the proportion of infected mosquitoes with RVFV positive legs and saliva, respectively. Three replicate experiments were performed, and individual data from those experiments are available in S1 Table. Hamster viremia in replicate three was low and resulted in low mosquito infection rates. Replicate two infection frequencies were significantly higher than replicate one for both treatments and at both day 7 and day 14 (P < 0.0001) (S1 Table) . However, Fig 1 and S1 RVFV body (Fig 2A) and saliva titers ( Fig 2B) were determined for Wolbachia-infected and control Cx. tarsalis. There were no significant differences in RVFV body titer or saliva titer between Wolbachia-infected and control Cx. tarsalis at either day 7 (Fig 2A) or day 14 (Fig  2B) . Additionally, when replicate data were pooled, both Wolbachia-infected and uninfected Cx. tarsalis that had higher RVFV body titers were more likely to have RVFV-positive saliva (S1 Fig). 
Quantitative real-time PCR of Wolbachia (wAlbB) density
We performed qPCR from the DNA of each mosquito and determined Wolbachia density as an expression normalized to a reference gene, actin [40] . We used all samples that were positive for Wolbachia to analyze relationships between Wolbachia density and RVFV body titer; we combined data from all replicate experiments (Fig 3) . Overall, there was a moderate, negative correlation between Wolbachia density and RVFV body titer at both day 7 and 14 ( Fig 3A and 3B) . Replicate two, the replicate with the highest infection rates, did not have significant correlations between Wolbachia density and RVFV body titer at either day 7 (n = 14, r = 0.0516, p = 0.062) or day 14 (n = 27, r = 0.112, p = 0.577) (raw data available S2 Table) . Wolbachia density was also compared across time; Wolbachia concentration at day 14 was significantly higher than at day 7, consistent with Wolbachia replication in mosquitoes (S3 Fig). 
Discussion
Wolbachia infection can have varied effects on viruses and parasites transmitted by mosquitoes. These effects can include moderate to complete pathogen inhibition, as well as pathogen enhancement [17, 22, 24, 41, 42] . In a previous study, we found that Wolbachia strain wAlbB enhanced WNV infection frequency in Cx. tarsalis [24] , although in that study, viral infection titers were not measured. To understand how widespread the Wolbachia-induced enhancement phenotype is in Cx. tarsalis, we studied wAlbB effects on RVFV, an important arthropod-borne virus with potential to invade the United States [43, 44] . In contrast to our previous results, we found that wAlbB did not affect RVFV body or saliva titers, nor RVFV infection, dissemination, or transmission frequencies in Cx. tarsalis.
Wolbachia-mediated effects on pathogens may depend on Wolbachia density. Several studies have reported that high densities of Wolbachia are more likely than low densities to block viruses in Drosophila spp. and mosquitoes [45] [46] [47] [48] . Similarly, we found a moderate, negative correlation between RVFV body titer and Wolbachia density. High Wolbachia levels were associated with RVFV negative mosquitoes or those with low RVFV body titers. The low numbers of mosquitoes at the high Wolbachia densities may explain why we did not see a Wolbachia effect on population level vector competence measures. However, our correlation data suggests that in this system, Wolbachia may suppress RVFV in a density-dependent manner.
In this Cx. tarsalis-wAlbB system, we have reported different effects of Wolbachia on vector competence for WNV and RVFV [24] . Other studies have found similar differences in Wolbachia phenotypes and suggested they may depend on various factors including environmental conditions, and pathogen type [20, 49] . RVFV and WNV belong to different virus families and could interact with the mosquito host environment and Wolbachia in different ways. For example, a recent study suggested that the mosquito JAK/STAT pathway may not have the same antiviral effects on closely related viruses [50] . Although the mosquitoes in our two studies have the same genetic background, they were reared in separate facilities and may have different microbiomes that may explain differences in vector competence [51] .
While artificial feeding methods such as membrane feeders or pledgets allow one to easily standardize viral titers, previous studies on mosquito RVFV and other virus infections demonstrated significantly reduced mosquito infectivity using an artificial feeding system compared to a live infected animal [52, 53] . We therefore decided to use live hamsters infected with a highly virulent and epidemiologically relevant viral strain in our experiments. However, this more biologically relevant choice comes with a trade-off; it is impossible to standardize the viral titer in a live animal infection model. While all hamsters were infected with approximately the same amount of virus, they varied in their response to the infection, resulting in significant variation in final viral blood titers across experimental replicates that reduced statistical power.
Our study was performed with an adult microinjection model that generates mosquitoes transiently infected with Wolbachia. It remains to be seen whether this model reflects relationships between Wolbachia and viruses in Cx. tarsalis in a stable infection system. However, a recent study showed that both stable and transient wAlbB infections in Ae. aegypti produced similar results [45] . This suggests that our transient infection model may correlate with a stable infection in Cx. tarsalis.
Despite relatively modest measurable effects in these experiments, our results underscore the necessity of studying diverse Wolbachia-host-pathogen systems. It is becoming increasingly clear that one cannot extrapolate results of one system of interactions across all systems; every Wolbachia-host-pathogen system must be individually examined. Future studies should seek to understand the mechanisms underlying variation of Wolbachia protective effects across diverse mosquito species, viral/pathogen species, and Wolbachia strains.
Supporting information S1 Table. Vector competence of Cx. tarsalis following a RVFV blood meal. RVFV infection, dissemination, and transmission frequencies were compared between Wolbachia-infected and Normalized Wolbachia levels and RVFV body titer for each mosquito were plotted and analyzed with the Spearman rank correlation test to determine relationships. There was a moderate, negative correlation between RVFV body titer and Wolbachia levels at both day 7 (n = 46) (A) and day 14 (n = 54) (B) post-blood feeding (Fig 3) . Data for all replicates were combined; see S2 Table for replicate-specific raw data. 
